120 related articles for article (PubMed ID: 27514505)
1. Coinhibition of overexpressed genes in acute myeloid leukemia subtype M2 by gold nanoparticles functionalized with five antisense oligonucleotides and one anti-CD33(+)/CD34(+) aptamer.
Zaimy MA; Jebali A; Bazrafshan B; Mehrtashfar S; Shabani S; Tavakoli A; Hekmatimoghaddam SH; Sarli A; Azizi H; Izadi P; Kazemi B; Shojaei A; Abdalaian A; Tavakkoly-Bazzaz J
Cancer Gene Ther; 2016 Sep; 23(9):315-20. PubMed ID: 27514505
[TBL] [Abstract][Full Text] [Related]
2. [Screening and structure analysis of nucleic acid aptamers binding to surface of CD33(+)/CD34(+) cells from patients with acute myeloid leukemia subtype M₂].
Zhang SQ; Wang GP; Zhu P; Liang JJ; Xu YJ; Peng MY; Chen Y; Tan SQ; Chen FP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):561-5. PubMed ID: 21729522
[TBL] [Abstract][Full Text] [Related]
3. [In vitro selection of single strand deoxyribonucleic acid aptamers binding to cells from patients with acute myeloblastic leukemia].
Zhu P; Wang G; Zhang S; Xu Y; Peng M; Yin H; Chen Y; Tan S; Chen F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 37(8):771-6. PubMed ID: 22954922
[TBL] [Abstract][Full Text] [Related]
4. Hybridization of different antisense oligonucleotides on the surface of gold nanoparticles to silence zinc metalloproteinase gene after uptake by Leishmania major.
Jebali A; Anvari-Tafti MH
Colloids Surf B Biointerfaces; 2015 May; 129():107-13. PubMed ID: 25835145
[TBL] [Abstract][Full Text] [Related]
5. FLT3 Internal Tandem Duplication Mutation, cMPL and CD34 Expressions Predict Low Survival in Acute Myeloid Leukemia Patients.
Ebrahim EK; Assem MM; Amin AI; Kamel MM; El Meligui YM; Metwally AM
Ann Clin Lab Sci; 2016 Dec; 46(6):592-600. PubMed ID: 27993871
[TBL] [Abstract][Full Text] [Related]
6. Rapid identification of specific DNA aptamers precisely targeting CD33 positive leukemia cells through a paired cell-based approach.
Yang C; Wang Y; Ge MH; Fu YJ; Hao R; Islam K; Huang P; Chen F; Sun J; Hong F; Naranmandura H
Biomater Sci; 2019 Feb; 7(3):938-950. PubMed ID: 30519686
[TBL] [Abstract][Full Text] [Related]
7. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.
Laing AA; Harrison CJ; Gibson BES; Keeshan K
Exp Hematol; 2017 Oct; 54():40-50. PubMed ID: 28668350
[TBL] [Abstract][Full Text] [Related]
8. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
Laszlo GS; Harrington KH; Gudgeon CJ; Beddoe ME; Fitzgibbon MP; Ries RE; Lamba JK; McIntosh MW; Meshinchi S; Walter RB
Oncotarget; 2016 Jul; 7(28):43281-43294. PubMed ID: 27248327
[TBL] [Abstract][Full Text] [Related]
9. CD33-targeting extracellular vesicles deliver antisense oligonucleotides against FLT3-ITD and miR-125b for specific treatment of acute myeloid leukaemia.
Chen H; Jayasinghe MK; Yeo EYM; Wu Z; Pirisinu M; Usman WM; Pham TT; Lim KW; Tran NV; Leung AYH; Du X; Zhang Q; Phan AT; Le MTN
Cell Prolif; 2022 Sep; 55(9):e13255. PubMed ID: 35851970
[TBL] [Abstract][Full Text] [Related]
10. A CD33 Antigen-Targeted AAV6 Vector Expressing an Inducible Caspase-9 Suicide Gene Is Therapeutic in a Xenotransplantation Model of Acute Myeloid Leukemia.
Khan N; Bammidi S; Jayandharan GR
Bioconjug Chem; 2019 Sep; 30(9):2404-2416. PubMed ID: 31436412
[TBL] [Abstract][Full Text] [Related]
11. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
[TBL] [Abstract][Full Text] [Related]
12. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy.
Luo YL; Shiao YS; Huang YF
ACS Nano; 2011 Oct; 5(10):7796-804. PubMed ID: 21942498
[TBL] [Abstract][Full Text] [Related]
13. Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure.
Imrichova D; Messingerova L; Seres M; Kavcova H; Pavlikova L; Coculova M; Breier A; Sulova Z
Eur J Pharm Sci; 2015 Sep; 77():29-39. PubMed ID: 26002042
[TBL] [Abstract][Full Text] [Related]
14. Double targeting, controlled release and reversible delivery of daunorubicin to cancer cells by polyvalent aptamers-modified gold nanoparticles.
Taghdisi SM; Danesh NM; Lavaee P; Emrani AS; Hassanabad KY; Ramezani M; Abnous K
Mater Sci Eng C Mater Biol Appl; 2016 Apr; 61():753-61. PubMed ID: 26838906
[TBL] [Abstract][Full Text] [Related]
15. [Multidrug resistance in acute leukemia].
Takeshita A; Ohno R
Rinsho Ketsueki; 1996 Aug; 37(8):640-6. PubMed ID: 8827870
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
O'Hear C; Heiber JF; Schubert I; Fey G; Geiger TL
Haematologica; 2015 Mar; 100(3):336-44. PubMed ID: 25480499
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
18. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
19. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
[TBL] [Abstract][Full Text] [Related]
20. Efficient delivery of the Bcl-2 antisense oligonucleotide G3139 via nucleus-targeted aCD33-NKSN nanoparticles.
Yan C; Gu J; Zhang Y; Ma K; Lee RJ
Int J Pharm; 2022 Sep; 625():122074. PubMed ID: 35932928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
